Date: 2015-09-15
Type of information: Establishment of a new subsidiary in the US
Compound:
Company: Curevac (Germany)
Therapeutic area: Infectious diseases
Type agreement: establishment of a new subsidiary in the US
Action mechanism:
Disease:
Details: * On September 10, 2015, CureVac announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines. Headquartered in T?bingen, Germany, where CureVac was founded in 2000 as a spin-off of the University, the expansion into the U.S. extends the company’s footprint into one of the world’s preeminent biotechnology hubs. The US subsidiary will be headed by Karen Slobod, MD, as managing director, formerly Head of the Maternal Immunization Franchise at Novartis Vaccines, and will primarily focus on development activities involving CureVac’s rapidly growing pipeline of mRNA-based prophylactic vaccines, which include programs targeting Rotavirus, RSV, HIV, and influenza virus in collaborations with the Bill & Melinda Gates Foundation, IAVI and Johnson & Johnson. Additionally, the U.S. operations will enable CureVac to more directly engage the U.S. pharmaceutical and investor communities.
CureVac’s technology utilizes natural, chemically unmodified mRNA to develop a broad range of therapeutic candidates in cancer immunotherapies and prophylactic vaccines as well as molecular therapy. To date, CureVac has validated its approach in numerous clinical trials, including an ongoing Phase IIb study in prostate cancer. A recent study published in Molecular Therapy demonstrated that CureVac’s mRNAs are also able to raise relevant protein levels without stimulating an unwanted immune reaction and achieved meaningful biological responses.
Financial terms:
Latest news:
